# OnCo record prelude-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/prelude-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "prelude-therapeutics" ;
  schema:name "Prelude Therapeutics"@en ;
  schema:description "Prelude Therapeutics develops precision cancer medicines. Its current focus is a pill for blood cancers driven by a JAK2 mutation and drugs that destroy a protein called KAT6A in hormone-driven breast cancer."@en ;
  schema:url <https://onco.cc/companies/prelude-therapeutics/>, <https://preludetx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://preludetx.com/>, <https://preludetx.com/science/pipeline/>, <https://www.sec.gov/Archives/edgar/data/1678660/000156459020052741/prld-ex991_6.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/epigenetics/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/degrader-antibody-conjugate/>, <https://onco.cc/technologies/epigenetic-drugs/> .